BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...to review growth hormone agonist from Pfizer and OpkoPfizer Inc. (NYSE:PFE) and Opko Health Inc. (NASDAQ:OPK...
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...hormone therapy from Pfizer, Opko meets in Phase IIIPfizer Inc. (NYSE:PFE) and Opko Health Inc. (NASDAQ:OPK...
BioCentury | Mar 29, 2019
Clinical News

Opko's diabetes therapy meets in Phase IIb

...had inadequate glucose control with metformin and/or diet and exercise. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Switzerland Loxo Oncology Inc. (NASDAQ:LOXO), Stamford, Conn. Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Opko Health Inc. (NASDAQ:OPK...
BioCentury | Nov 16, 2018
Financial News

Opko raises $92.5M in private placement

...Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) raised $92.5 million in a private placement on Nov. 8...
...credit agreement were announced in a Nov. 9 SEC filing. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Sep 7, 2018
Financial News

Opko's Frost among those charged in ‘pump-and-dump’ schemes

...penny stock companies. Frost, who is chairman and CEO at Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Jul 6, 2018
Financial News

Biotech stocks rise after positive AD data

...Immune S.A. (NASDAQ:ACIU), which added $3.56 (38%) to $12.86, and Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Jan 19, 2018
Clinical News

Tesaro informs doctors of hypersensitivity risks with Varubi

...NK1R; TACR1) antagonist from Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK). Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Jan 9, 2018
Finance

Stars in China

...protein 65kDa (RPE65) mutation-associated retinal dystrophy Tesaro Inc. (NASDAQ:TSRO) / Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Nov 3, 2017
Clinical News

FDA approves Tesaro's Varubi rolapitant IV to prevent CINV

...rights to the neurokinin 1 receptor (NK1R; TACR1) antagonist from Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
...EU for the same indication (see BioCentury, May 4 ). Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
Items per page:
1 - 10 of 202
BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...to review growth hormone agonist from Pfizer and OpkoPfizer Inc. (NYSE:PFE) and Opko Health Inc. (NASDAQ:OPK...
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...hormone therapy from Pfizer, Opko meets in Phase IIIPfizer Inc. (NYSE:PFE) and Opko Health Inc. (NASDAQ:OPK...
BioCentury | Mar 29, 2019
Clinical News

Opko's diabetes therapy meets in Phase IIb

...had inadequate glucose control with metformin and/or diet and exercise. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Switzerland Loxo Oncology Inc. (NASDAQ:LOXO), Stamford, Conn. Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Opko Health Inc. (NASDAQ:OPK...
BioCentury | Nov 16, 2018
Financial News

Opko raises $92.5M in private placement

...Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) raised $92.5 million in a private placement on Nov. 8...
...credit agreement were announced in a Nov. 9 SEC filing. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Sep 7, 2018
Financial News

Opko's Frost among those charged in ‘pump-and-dump’ schemes

...penny stock companies. Frost, who is chairman and CEO at Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Jul 6, 2018
Financial News

Biotech stocks rise after positive AD data

...Immune S.A. (NASDAQ:ACIU), which added $3.56 (38%) to $12.86, and Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Jan 19, 2018
Clinical News

Tesaro informs doctors of hypersensitivity risks with Varubi

...NK1R; TACR1) antagonist from Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK). Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Jan 9, 2018
Finance

Stars in China

...protein 65kDa (RPE65) mutation-associated retinal dystrophy Tesaro Inc. (NASDAQ:TSRO) / Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
BioCentury | Nov 3, 2017
Clinical News

FDA approves Tesaro's Varubi rolapitant IV to prevent CINV

...rights to the neurokinin 1 receptor (NK1R; TACR1) antagonist from Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
...EU for the same indication (see BioCentury, May 4 ). Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK...
Items per page:
1 - 10 of 202